In this episode, Dr. Aly-Khan Lalani, Dr. Christopher Wallis, and Dr. Alex Wyatt walk through the fundamentals of clinical genomics and why it matters for routine practice. They discuss which alterations matter in prostate cancer, germline vs. somatic testing, ctDNA test use cases and limits, and more.Dr. Alex Wyatt is an Associate Professor in Urologic Sciences and holds the President’s Excellence Chair in Precision Oncology at the University of British Columbia. He is also a Senior Scientist at the Vancouver Prostate Centre and BC Cancer, where his work focuses on advancing clinical genomics and precision oncology in prostate cancer.This podcast has been made possible through unrestricted financial support by Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related